Dendritic Cell Immunotherapy for the Patients With Pancreatic Cancer
NCT ID: NCT03114631
Last Updated: 2019-12-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
30 participants
INTERVENTIONAL
2017-01-09
2019-05-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Preoperative Intratumor Dendritic Cells Injection Immunotherapy for Patients With Pancreatic Cancer
NCT00795977
DC Vaccine in Pancreatic Cancer
NCT03592888
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
NCT06435351
A Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Pancreatic Adenocarcinoma
NCT01677962
Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients
NCT02766348
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Two options for dendritic cell priming are used: MUC-1/WT-1 peptides for the patients with unresectable tumor and/or tumor lysates for the patients undergoing tumor resection.
The dendritic cells are them matured and injected subcutaneous (all patients) and intratumorally (when possible).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dendritic cells lysate-pulsed group
Patients treated according to clinical protocols plus autologous dendritic cells, pulsed with tumor lysate
Dendritic cells pulsed with tumor lysate
Control group
Patients treated according to clinical protocols
No interventions assigned to this group
Dendritic cells peptide-pulsed group
Patients treated according to clinical protocols plus autologous dendritic cells, pulsed with MUC-1/WT-1 peptides
Dendritic cells pulsed with MUC-1/WT-1 peptides
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dendritic cells pulsed with tumor lysate
Dendritic cells pulsed with MUC-1/WT-1 peptides
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HLA-A2 expression by tumor cells;
* WT-1/MUC-1 expression by tumor cells.
Exclusion Criteria
* pregnancy/lactation;
* intercurrent severe chronic diseases;
* HIV, Hepatites B/C;
* active tuberculosis;
* alcohol use disorder/drug addiction.
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Belarusian State Medical University
OTHER
The Republican Research and Practical Center for Epidemiology and Microbiology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Andrei Y. Hancharou
Head of the Laboratory for Immunology and Cellular Biotechnology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alexander V. Prokharau, Prof.
Role: STUDY_DIRECTOR
Belarussian State Medical University, Minsk, Belarus
Andrei Y Hancharou, Dr.
Role: STUDY_DIRECTOR
The Republican Research and Practical Center for Epidemiology and Microbiology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Minsk City Clinical Oncologic Dispensary
Minsk, , Belarus
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RRPCEM_DC1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.